Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
arm A:Ribavirin + Interferon alpha-1b
arm B:lopinavir / ritonavir + interferon alpha-1b
arm C:Ribavirin + LPV/r+Interferon alpha-1b
Sponsors
Chongqing Public Health Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) 18–65 years of age; (2) Diagnosed as mild to moderate COVID-19; (3) Be willing to sign informed consent; (4) The clinical assessment and condition of the subject does not influence the completion of the study.
Exclusion criteria
Exclusion criteria: (1) Patients are diagnosed as a case of severe NCIP; (2) Patients are pregnant or breastfeeding women; (3) Patients have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5×UNL or creatinine clearance <50 ml / min; (4) Patients are allergic or intolerant to the proposed antiviral therapeutic drugs; (5) Patients are HIV-positive; (6) Patients with hemoglobin disease (7) Patients have severe heart disease, brain disease, lung disease, kidney disease, tumor or other severe systemic diseases; (8) Patients are not willing to provide signed informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time to 2019-nCoV RNA negativity in patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| mortality on day 28;The rate of negative 2019-nCoV RNA results at day 14;the rate of aggravation;the rate of adverse events ;The rate of discontinuations due to adverse events; | — |
Countries
China
Contacts
Public ContactYaokai Chen
Chongqing Public Health Medical Center
Outcome results
None listed